Related Articles

• KRAS mutations and subtyping in colorectal cancer in Jordanian patients
• Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models
• Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation
• EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
• Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival